Homepage - MedDay Pharma

______________________________________

ABOUT US

______________________________________

RESEARCH & DEVELOPMENT

_____________________________________

FOR PATIENTS & FAMILIES

______________________________________

THERAPEUTIC AREAS

______________________________________

CAREERS

______________________________________

NEWS & EVENTS

______________________________________

FIND US

“We are the world leader in exploring brain metabolism with the goal of discovering new therapies.“

Frédéric Sedel, 2017

Our story

Investigating neurodegenerative diseases from a different perspective.

Our pipeline

Our pipeline currently comprises one lead candidate targeting Progressive Multiple Sclerosis and other neurodegenerative disorders, including Charcot-Marie-Tooth Disease and Hepatic Encephalopathy.

Progressive Multiple Sclerosis

To establish effective therapies for Progressive Multiple Sclerosis is one of the greatest priorities for the global Multiple Sclerosis community.

MD1003: high dose Pharmaceutical grade Biotin

MedDay’s lead candidate, MD1003, is a patented oral formulation of high dose Pharmaceutical grade Biotin that is being developed in progressive forms of Multiple Sclerosis.

For Patients and Families

At MedDay, we are driven by patient needs and outcomes, placing people living with neurodegenerative conditions and their families at the heart of everything we do.

July 22nd, 2019

MedDay Pharmaceuticals to webcast key opinion leader meeting on new treatment strategies for progressive forms of multiple sclerosis tomorrow

November 09th, 2018

MedDay Pharmaceuticals Announces Full Patient Enrollment for MD1003 Phase III Clinical Trial (SPI2) in Progressive Multiple Sclerosis

July 26th, 2018

MedDay Appoints Industry Leader Christian Chavy as Chief Executive Officer

Careers

Committed to patients, our passionate teams are investigating brain metabolism therapies, utilizing an innovative approach, with the goal of transforming the lives of people affected by serious neurodegenerative conditions.